1 w (P < 0.05); this response was inhibited by bretylium.

2 lation, with at least comparable efficacy to bretylium, a drug with a similar indication.

3 s not interact with or impact the binding of bretylium, a quaternary ammonium phenylmethylamine deriv

4                                 We show that bretylium acts in accord with the restitution hypothesis

5 (L-NMMA) was administered in the presence of bretylium and phentolamine prior to another bout of hand

6 o exercise and post-exercise ischaemia after bretylium and phentolamine.

7 rticular, we identify the action of the drug bretylium as a prototype for the future development of e

8 etic delivery of tyramine, phentolamine, and bretylium followed by a norepinephrine dose response.

9                      In skin pretreated with bretylium, the increase caused by nicotine in the initia

10 rmed after brachial artery administration of bretylium (to block noradrenaline release) and phentolam

11 olutions of yohimbine + propranolol (Y + P), bretylium tosylate (BT), and lactated Ringer solution we

12                                              Bretylium tosylate (BT), to block adrenergic function, w

13 olamine (non-selective alpha-antagonist) and bretylium tosylate (inhibits neurotransmission of adrene

14 roprusside, SNP); adrenergic blockade (10 mM bretylium tosylate); and low-dose (0.1 microM) noradrena

15 g was also applied to a site pretreated with bretylium via iontophoresis to inhibit noradrenergic neu

16 as refractory to lidocaine, procainamide and bretylium were randomized to receive one of three doses